| Budget Amount *help |
¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
Fiscal Year 2010: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2009: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Research Abstract |
We discovered in 2007 that a chromosomal rearrangement inv(2)(p21p23) in lung cancer generates a novel oncogene EML4-ALK which produces a constitutively activated, fusion protein between the amino-terminal half of a microtubule-associated protein EML4 and the catalytic domain of ALK. Clinical trials with ALK inhibitors are ongoing worldwide, and one of such early trials has already proved a marked efficacy of the compound against EML4-ALK-positive lung cancer. The swift introduction of ALK inhibitors to clinics raises a concern as to how EML4-ALK-positive tumors are diagnosed both accurately and sensitively. Here we developed multiplex RT-PCR system to capture EML4-ALK cDNAs, and further proved such technology to be a reliable means for clinical use.
|
